Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikko Neuvonen

Showing results (21-30 of 104) with videos related to

Pageof 11
Sort By:
Clinical Pharmacology and Therapeutics|October 19, 2002
Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazoleKari Raaska, Mikko Niemi, Mikko Neuvonen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 18, 2022
Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugsFeng Deng, Noora Sjöstedt, Mariangela Santo, et al.
British Journal of Clinical Pharmacology|January 5, 2006
Effect of rifampicin on the pharmacokinetics of pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.
European Journal of Clinical Pharmacology|May 4, 2006
Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|August 29, 2006
Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjectsJanne T Backman, Marjo J Karjalainen, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|March 18, 2004
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsMikko Niemi, Lauri I Kajosaari, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|July 27, 2005
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinideMikko Niemi, Janne T Backman, Laura Juntti-Patinen, et al.
Clinical Pharmacology and Therapeutics|April 3, 2004
Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interactionMarika T Granfors, Janne T Backman, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|September 18, 2004
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinideLauri I Kajosaari, Janne T Backman, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|July 5, 2003
Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinideMikko Niemi, Mikko Neuvonen, Laura Juntti-Patinen, et al.
Pageof 11

Showing results (21-30 of 104) with videos related to

Sort By:
Pageof 11
Clinical Pharmacology and Therapeutics|October 19, 2002
Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazoleKari Raaska, Mikko Niemi, Mikko Neuvonen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 18, 2022
Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugsFeng Deng, Noora Sjöstedt, Mariangela Santo, et al.
British Journal of Clinical Pharmacology|January 5, 2006
Effect of rifampicin on the pharmacokinetics of pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.
European Journal of Clinical Pharmacology|May 4, 2006
Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|August 29, 2006
Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjectsJanne T Backman, Marjo J Karjalainen, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|March 18, 2004
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsMikko Niemi, Lauri I Kajosaari, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|July 27, 2005
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinideMikko Niemi, Janne T Backman, Laura Juntti-Patinen, et al.
Clinical Pharmacology and Therapeutics|April 3, 2004
Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interactionMarika T Granfors, Janne T Backman, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|September 18, 2004
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinideLauri I Kajosaari, Janne T Backman, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|July 5, 2003
Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinideMikko Niemi, Mikko Neuvonen, Laura Juntti-Patinen, et al.
Pageof 11